1
|
Abstract
PURPOSE OF REVIEW The use of cytokines in harnessing the immune system to eradicate cancer has been an important treatment modality. However, the dose-limiting toxicities of these cytokines limited their usage in clinic. Here, we review the basic biology of cytokines involved in the treatment of melanoma and discuss their therapeutic applications. Moreover, we describe several innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacy of these cytokines. RECENT FINDINGS The safety and the anti-tumor activity of newly engineered cytokines including PEGylated IL-2 (NKTR-214), PEGylated IL-10 (AM0010), and IL-15 super agonist (ALT-803) have been evaluated in clinical trials with encouraging clinical activity and acceptable safety profile, both as single agents and in combination with immuno-oncology agents. A greater understanding of the mechanisms of action and effective dosing of these newly engineered cytokine together with determination of optimum combination therapy regimens may yield greater clinical benefits in the future.
Collapse
|
2
|
Abstract
PURPOSE OF REVIEW Interleukin-10 (IL-10) is a cytokine with anti-inflammatory properties, which induces activation and proliferation of antigen-activated intratumoral CD8+ T cells. This review discusses the evolution of pegylated IL-10 (pegilodecakin) from preclinical investigation through first-in-human studies in oncology. RECENT FINDINGS Pegilodecakin was evaluated across multiple advanced solid tumors in a large phase 1/1b trial alone and in combination with chemotherapy or anti-PD-1 antibodies. Pegilodecakin monotherapy had immunologic and clinical activity in renal cell carcinoma (RCC) and uveal melanoma. In combination with anti-PD-1 inhibitors, pegilodecakin increased the responses in RCC and lung cancer with efficacy agnostic to PD-L1 status and tumor mutational burden. Pegilodecakin with FOLFOX had activity in pretreated pancreatic cancer, instructing the ongoing randomized phase III trial of the combination versus FOLFOX. The increased half-life of pegilodecakin enabled compelling preclinical data for IL-10 which has now been confirmed by clinical activity in a variety of cancers. The ability of pegilodecakin to both exert anti-tumor immunity and inhibit tumor-associated inflammation characterizes the uniqueness of this cytokine therapy.
Collapse
Affiliation(s)
- Karen Autio
- Genitourinary Oncology Service/Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. .,Weill Cornell Medicine, New York, NY, USA.
| | | |
Collapse
|
3
|
Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8 + T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell 2018; 34:775-791.e3. [PMID: 30423297 PMCID: PMC8098754 DOI: 10.1016/j.ccell.2018.10.007] [Citation(s) in RCA: 147] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2017] [Revised: 06/12/2018] [Accepted: 10/15/2018] [Indexed: 12/28/2022]
Abstract
Tumor-reactive T cell exhaustion prevents the success of immune therapies. Pegilodecakin activates intratumoral CD8+ T cells in mice and induces objective tumor responses in patients. Here we report that pegilodecakin induces hallmarks of CD8+ T cell immunity in cancer patients, including elevation of interferon-γ and GranzymeB, expansion and activation of intratumoral CD8+ T cells, and proliferation and expansion of LAG-3+ PD-1+ CD8+ T cells. On pegilodecakin, newly expanded T cell clones, undetectable at baseline, become 1%-10% of the total T cell repertoire in the blood. Elevation of interleukin-18, expansion of LAG-3+ PD-1+ T cells and novel T cell clones each correlated with objective tumor responses. Combined pegilodecakin with anti-PD-1 increased the expansion of LAG-3+ PD-1+ CD8+ T cells.
Collapse
Affiliation(s)
- Aung Naing
- MD Anderson Cancer Center, Houston, TX, USA
| | - Jeffrey R Infante
- Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN, USA
| | | | - Ivan H Chan
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | - Cong Shen
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Navneet P Ratti
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | - Bianca Rojo
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | - Karen A Autio
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Deborah J Wong
- University of California Los Angeles (UCLA), Los Angeles, CA, USA
| | - Manish R Patel
- Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL, USA
| | | | | | | | - Annie Hung
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | - Kara L Pekarek
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | - Victoria Wu
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | - Matthew Adamow
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Scott McCauley
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | - John B Mumm
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | - Phillip Wong
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Joseph Leveque
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA
| | | | - Martin Oft
- ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.
| |
Collapse
|